TUC-S.R.L.
Just over a month after the Digital World Premiere, TUC.tiny is ready to make its debut at VivaTech 2024, the most important technology fair in Europe. In Hall 1, Pavilion 41, TUC S.r.l. will present to the public for the first time its latest technological innovation: TUC.tiny®, the Modular Dashboard concept, and the TUC.technology offering, developed to revolutionize the world of mobility.
TUC.tiny® is the compact version of the industrialized technology launched last year, based on the TUC.technology® patent and released in over 140 countries. It is currently the subject of collaborations with industry leaders such as ZER01NE, the Hyundai Motor Group's Open Innovation Platform, for the development of "Human-centric" vehicles.
This technological gem is based on the three pillars of TUC: mechanical structure, electronic management, and data exchange. Thanks to the integration of USB Type-C technology, TUC.tiny® aims to reinvent the interaction between users and vehicles, converging mobility and everyday life.
The result of advanced research by TUC S.r.l. in technological miniaturization and simplification, TUC.tiny® represents the core of the company's patented technology, designed to innovate the value chain in the mobility sector with a "human-centric" approach. It is an ideal solution for both the main players in the sector and users, representing a perfect synthesis of their needs.
The Modular Dashboard, developed to showcase the potential of TUC.tiny®, is a true blank canvas, customizable infinite times thanks to TUC.tiny® and TUC.technology®. An environment to inhabit and configure without limits, adapting functionally and flexibly to the needs of users.
With TUC.tiny® and its advanced interface - including physical fastening, electrical connectivity, and data transfer - any device can be integrated into the modular dashboard design, making it immediately operational. TUC.tiny® supports all everyday devices with USB Type-C connection, distinguishing itself by seamlessly blending into any part of the vehicle. Its robustness is ensured by a mechanical or electro-actuated locking mechanism, introducing the novelty of NFC technology for added security.
The introduction of TUC.tiny® completes the TUC.technology® offering, marking a step forward towards the democratization of technology. The gateway to an advanced mobility experience becomes wider, easily accommodating the smart objects that animate our daily lives.
TUC.tiny® and TUC.technology® embody the vision of the mobility ecosystem of the future: interconnected, multimodal, circular, and dynamic. This technology not only connects but synthesizes different spheres of our lives, making mobility more accessible, customizable, and environmentally conscious.
TUC invites everyone to imagine and build together a world where technology unites us, improving every aspect of our daily journey. The project, which started in the automotive sector, now aims to scale the technology to new verticals such as aerospace and marine sectors.
“The World Premiere of TUC.tiny® at VivaTech 2024 is an important recognition for TUC.technology as an enabler of the Mobility of the Future," said Ludovico Campana, Inventor and CEO of TUC. “TUC.tiny® represents our promise for the future: the vision of a world where technology and mobility create personalized experiences designed around the needs of each individual. This is the future that TUC S.r.l. is building: a mobility ecosystem driven by the values of democratization, personalization, and sustainability."
TUC.tiny® and the Modular Dashboard are ready to be showcased live to the public at VivaTech 2024, demonstrating that this vision is already a reality.
For more information, visit the "NEWSROOM" section of the website: https://www.tuc.technology/newsroom.
ABOUT TUC.technology
TUC S.r.l. is a leading Deep-Tech company in mobility innovation, specializing in the development of modular solutions for vehicles that aim to simplify and revolutionize the concept of a vehicle. Distinguished by technological excellence on an international level, TUC has received significant recognitions, including exhibitions at CES in Las Vegas and the National Automobile Museum.
With the launch of TUC 3.0, the company sets new standards in the sector, collaborating with major global OEMs. Learn more at http://www.tuc.technology.
Facebook @TUCtechnology
Instagram @tuc.technology
Twitter @TUCtechnology
Linkedin @TUC.technology
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240515972855/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom